Spots Global Cancer Trial Database for TIL for Patients With Advanced Solid Tumor
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: TIL for Patients With Advanced Solid Tumor
Official Title: Tumor Infiltrating Lymphocyte (TIL) Therapy for the Treatment of Advanced Solid Tumors
Study ID: NCT06334783
Conditions
Interventions
Study Description
Brief Summary: Background: Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy by harvesting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro and then infusing back to patients. TIL therapy has shown strong efficacy for the treatment of solid tumors and has achieved high objective response rates in multiple cancers, such as melanoma, NSCLC, and cervical cancer. Objective: To evaluate the safety and efficacy of TIL for the patients with advanced solid tumor. Eligibility: Adults aging 18-75 with advanced solid tumor. Design: 1. Patients will undergo screening tests, including imaging procedures, heart and lung tests, and lab tests. 2. Freshly resected patient tumors were dissected by the surgeon. 3. TIL cells were isolated from the patient's tumor tissue, then cultured in vitro, activated and expanded. 4. At last TIL cells will be re-infused into the patients.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, Guangdong, China
Nanjing Jinling Hospital, Nanjing, Jiangsu, China
Wowen's hospital, School of medicine, Zhejiang University, Hangzhou, Zhejiang, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
